Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice

Abstract Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn’s disease―are commonly treated with biologic drugs. However, only approximately two-thirds of patients have an initial response to these therapies. Personalised medicine has the potential to optimise efficacy, decreas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Crohn's and colitis 2020-06, Vol.14 (5), p.694-709
Hauptverfasser:	Gisbert, Javier P, Chaparro, María
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - therapeutic use Age Factors Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers - blood Body Weight C-Reactive Protein - metabolism Certolizumab Pegol - therapeutic use Cytokines - blood Feces - microbiology Gastrointestinal Microbiome Humans Inflammatory Bowel Diseases - blood Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - genetics Infliximab - therapeutic use Integrins - blood Patient Acuity Phenotype Serum Albumin - metabolism Sex Factors Smoking Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Ustekinumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!